However, this approach presents clinical challenges and safety concerns, including hypo responsiveness to EPO, potential adverse effects such as hypertension and cardiovascular events, and the risk of iron overload, which warrants an in-depth study on novel drugs like HIF-PHI [33]. The gene discussed is EPO; the disease is Hypertension.